227 related articles for article (PubMed ID: 20682852)
1. siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells.
Hobo W; Maas F; Adisty N; de Witte T; Schaap N; van der Voort R; Dolstra H
Blood; 2010 Nov; 116(22):4501-11. PubMed ID: 20682852
[TBL] [Abstract][Full Text] [Related]
2. Efficient nontoxic delivery of PD-L1 and PD-L2 siRNA into dendritic cell vaccines using the cationic lipid SAINT-18.
Roeven MW; Hobo W; van der Voort R; Fredrix H; Norde WJ; Teijgeler K; Ruiters MH; Schaap N; Dolstra H
J Immunother; 2015 May; 38(4):145-54. PubMed ID: 25839440
[TBL] [Abstract][Full Text] [Related]
3. siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8(+) T cells in NOD/SCID/IL2Rg(null) mice.
van der Waart AB; Fredrix H; van der Voort R; Schaap N; Hobo W; Dolstra H
Cancer Immunol Immunother; 2015 May; 64(5):645-54. PubMed ID: 25724840
[TBL] [Abstract][Full Text] [Related]
4. siRNA knockdown of PD-L1 and PD-L2 in monocyte-derived dendritic cells only modestly improves proliferative responses to Gag by CD8(+) T cells from HIV-1-infected individuals.
Breton G; Yassine-Diab B; Cohn L; Boulassel MR; Routy JP; Sékaly RP; Steinman RM
J Clin Immunol; 2009 Sep; 29(5):637-45. PubMed ID: 19562472
[TBL] [Abstract][Full Text] [Related]
5. PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation.
Norde WJ; Maas F; Hobo W; Korman A; Quigley M; Kester MG; Hebeda K; Falkenburg JH; Schaap N; de Witte TM; van der Voort R; Dolstra H
Cancer Res; 2011 Aug; 71(15):5111-22. PubMed ID: 21659460
[TBL] [Abstract][Full Text] [Related]
6. Monocyte-Derived Dendritic Cells with Silenced PD-1 Ligands and Transpresenting Interleukin-15 Stimulate Strong Tumor-Reactive T-cell Expansion.
Van den Bergh JMJ; Smits ELJM; Berneman ZN; Hutten TJA; De Reu H; Van Tendeloo VFI; Dolstra H; Lion E; Hobo W
Cancer Immunol Res; 2017 Aug; 5(8):710-715. PubMed ID: 28637876
[TBL] [Abstract][Full Text] [Related]
7. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.
Brown JA; Dorfman DM; Ma FR; Sullivan EL; Munoz O; Wood CR; Greenfield EA; Freeman GJ
J Immunol; 2003 Feb; 170(3):1257-66. PubMed ID: 12538684
[TBL] [Abstract][Full Text] [Related]
8. Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation.
Hobo W; Novobrantseva TI; Fredrix H; Wong J; Milstein S; Epstein-Barash H; Liu J; Schaap N; van der Voort R; Dolstra H
Cancer Immunol Immunother; 2013 Feb; 62(2):285-97. PubMed ID: 22903385
[TBL] [Abstract][Full Text] [Related]
9. Efficient activation of LRH-1-specific CD8+ T-cell responses from transplanted leukemia patients by stimulation with P2X5 mRNA-electroporated dendritic cells.
Overes IM; Fredrix H; Kester MG; Falkenburg JH; van der Voort R; de Witte TM; Dolstra H
J Immunother; 2009; 32(6):539-51. PubMed ID: 19483655
[TBL] [Abstract][Full Text] [Related]
10. Anti-Tumor Potency of Short-Term Interleukin-15 Dendritic Cells Is Potentiated by
Versteven M; Flumens D; Campillo-Davó D; De Reu H; Van Bruggen L; Peeters S; Van Tendeloo V; Berneman Z; Dolstra H; Anguille S; Hobo W; Smits E; Lion E
Front Immunol; 2022; 13():734256. PubMed ID: 35250967
[TBL] [Abstract][Full Text] [Related]
11. B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation.
Hobo W; Norde WJ; Schaap N; Fredrix H; Maas F; Schellens K; Falkenburg JH; Korman AJ; Olive D; van der Voort R; Dolstra H
J Immunol; 2012 Jul; 189(1):39-49. PubMed ID: 22634623
[TBL] [Abstract][Full Text] [Related]
12. Co-immunizing with PD-L1 induces CD8
Guo S; Xiao P; Li B; Wang W; Wang S; Lv T; Xu X; Chen C; Huang L; Li Z; Tang L; Peng L; Wang H
Int Immunopharmacol; 2020 Jul; 84():106516. PubMed ID: 32334387
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1.
Song MY; Park SH; Nam HJ; Choi DH; Sung YC
J Immunother; 2011 Apr; 34(3):297-306. PubMed ID: 21389868
[TBL] [Abstract][Full Text] [Related]
14. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis.
Pittet CL; Newcombe J; Prat A; Arbour N
J Neuroinflammation; 2011 Nov; 8():155. PubMed ID: 22067141
[TBL] [Abstract][Full Text] [Related]
15. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1.
Ghiotto M; Gauthier L; Serriari N; Pastor S; Truneh A; Nunès JA; Olive D
Int Immunol; 2010 Aug; 22(8):651-60. PubMed ID: 20587542
[TBL] [Abstract][Full Text] [Related]
17. Programmed death ligand 1 (PD-L1) plays a vital part in DC tolerogenicity induced by IFN-γ.
Švajger U; Tešić N; Rožman P
Int Immunopharmacol; 2021 Oct; 99():107978. PubMed ID: 34298399
[TBL] [Abstract][Full Text] [Related]
18. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands.
Kinter AL; Godbout EJ; McNally JP; Sereti I; Roby GA; O'Shea MA; Fauci AS
J Immunol; 2008 Nov; 181(10):6738-46. PubMed ID: 18981091
[TBL] [Abstract][Full Text] [Related]
19. DEC-205-mediated antigen targeting to steady-state dendritic cells induces deletion of diabetogenic CD8⁺ T cells independently of PD-1 and PD-L1.
Mukherjee G; Geliebter A; Babad J; Santamaria P; Serreze DV; Freeman GJ; Tarbell KV; Sharpe A; DiLorenzo TP
Int Immunol; 2013 Nov; 25(11):651-60. PubMed ID: 24021877
[TBL] [Abstract][Full Text] [Related]
20. Fine-tuned expression of programmed death 1 ligands in mature dendritic cells stimulated by CD40 ligand is critical for the induction of an efficient tumor specific immune response.
Gu T; Zhu YB; Chen C; Li M; Chen YJ; Yu GH; Ge Y; Zhou SY; Zhou H; Huang Y; Qiu YH; Zhang XG
Cell Mol Immunol; 2008 Feb; 5(1):33-9. PubMed ID: 18318992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
